Advertisement

Topics

Companies Related to "Alexo Therapeutics Presents Preliminary Results from ALX148 Phase" [Most Relevant Company Matches] RSS

08:10 EDT 25th June 2018 | BioPortfolio

Here are the most relevant search results for "Alexo Therapeutics Presents Preliminary Results from ALX148 Phase" found in our extensive corporate database of over 50,000 company records.

Showing "Alexo Therapeutics Presents Preliminary Results from ALX148 Phase" Companies 1–25 of 3,500+

Extremely Relevant

Alexo Therapeutics

Alexo Therapeutics is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin....


Relevant

Vicus Therapeutics, LLC

Vicus Therapeutics is a biopharmaceutical company dedicated to bringing breakthrough therapies to patients with cancer. Vicus' lead investigational therapy, VT-122, is a combination of etodolac and propranolol. VT-122 showed positive results in a Phase 2 clinical trial of lung cancer patients and is currently being evaluated in a Phase 2 clinical trial of liver cancer patients receiving Nexavar ...

Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is currently in three Phase 3 clinical trials for the treatment of the psychotic features of psychotic major depression (PMD), a disorder that affects approximately three million adults in the United States ea...


vTv Therapeutics Inc. vTv Therapeutics Inc. vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflamma...

ACT Biotech Inc.

ACT Biotech (www.actbiotech.com) is a San Francisco-based, privately-held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs. The Company's clinical stage pipeline also includes Telatinib, the most selective oral VEGF/PDGFR/KIT inhibitor ever developed. Telatinib is currently being studied in a Phase 2 trial...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Cypress Bioscience

We are committed to being the innovator and leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other central nervous system disorders. Specifically, our strategy involves acquiring or in-licensing central nervous system, or CNS, active compounds and developing them for novel and typically underserved indications....

Synosia Therapeutics

Synosia Therapeutics is a privately owned company, which develops and intends to commercialise innovative, first or best-in-class products for unmet medical needs in neurology and psychiatry. Synosia utilises cutting-edge technologies and creative clinical study designs to de-risk its compounds before moving into larger, more extensive Phase II and Phase I...

Zelos Therapeutics Inc.

Zelos Therapeutics is an emerging private biopharmaceutical development company that is commercializing breakthrough discoveries in parathyroid hormone (PTH) research. The company is developing medications for the treatment of osteoporosis, psoriasis and for enhancing engraftment following stem cell transplantation. During 2005, Zelos Therapeutics experienced a number of significant milestones. Ke...

Azaya Therapeutics Inc.

Azaya Therapeutics, Inc. is an oncology company focused on developing more effective cancer treatments through its novel nanotechnology platform. Azaya’s patented Protein Stabilized Liposomes™ (PSL) platform allows for high-dose delivery of potent cytotoxics with potentially lower side effects. ATI-1123, is a novel liposomal encapsulation of Doce...

Tactical Therapeutics, Inc.

Tactical Therapeutics, Inc., is a privately funded company, that has developed a patented lead therapeutic, CTO, for glioblastoma and other solid cancers. Four Phase I trials in one hundred patients have been completed, and two Phase II trials are planned for rGBM and nGBM. The company is pursuing partnering, co-development and/or licensing strategies to e...

Affibody

Affibody has developed a unique pipeline of affinity ligands in oncology, covering the entire value chain from research reagents to molecular imaging agents and targeted therapeutics. The company has obtained outstanding clinical molecular imaging results and promising targeted therapeutics pre-clinical results. Affibody expects to launch one molecular imaging agent per year from 2007 and to file ...

PsiOxus Therapeutics, Ltd.

PsiOxus Therapeutics is a development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases. The Company’s lead candidate is MT-102, a dual action Anabolic Catabolic Transforming Agent (ACTA) in phase II clinical development for the treatment of cachexia and ...

Iconic Therapeutics

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and a...

Tarsa Therapeutics, Inc.

Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that inhibits bone resorption, the process underlying osteoporosis. Availability of an oral formulation is expected to generate wider use of this established osteoporosis treatment, which currently is available only in injectable and intranasal formulations. Tarsa's oral calcit...

Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a pharmaceutical company that has historically been focused on the discovery and development of product candidates for patients with cystic fibrosis, or CF. The Company's development candidates selectively target an enzyme known as S-nitrosoglutathione reductase (GSNOR). GSNOR regulates levels of an en...

Esperion Therapeutics Inc.

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally avail...

Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc.

Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a pharmaceutical company that has historically been focused on the discovery and development of product candidates for patients with cystic fibrosis, or CF. The Company’s development candidates selectively target an enzyme known as S-nitrosoglutathione reductase (GSNOR). GSNOR regulates levels of ...

Iconic Therapeutics, Inc.

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and a...

Elusys Therapeutics, Inc

Elusys Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of targeted anti-infective therapeutics using proprietary Heteropolymer (HP) Antibodies for the treatment of infectious disease. The Company’s most advanced product, Anthim™, a treatment for Anthrax infection, has entered Phase I human safety studies. Anthim represents a near-term revenue opportu...

Robin Dennison Presents, Inc

Robin Donohoe Dennison has 30 years of experience in critical care nursing, working as a staff nurse, nurse educator, clinical nurse specialist, consultant, and professor. Dr. Dennison’s educational background includes AA in nursing from Morris Harvey College (now University of Charleston) in Charleston, WV, BSN from Marshall University in Huntington, West Virginia, MSN in Cardiopulmonary Nursin...

Akebia Therapeutics, Inc.

Akebia Therapeutics is a discovery and development company focused on anemia and vascular disorders. Akebia’s lead program, AKB-6548, an orally bioavailable HIF-prolyl hydroxylase (HIF-PH) inhibitor for patients with anemia, is in phase 2 clinical trials. AKB-6548 potentially promises to be a safer, less expensive, orally dosed pharmaceutical to stimu...

CytoDyn Inc.

CytoDyn is a biotechnology company focused on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The Company has one of the leading mAbs under development for HIV infection PRO 140 which is a Late Stage II humanized mAb with dem...

EiRx Therapeutics Limited

The Company is based around original concepts and discoveries made by Prof. Tom Cotter (CSO). Tom is a leading international expert in this field and is Professor of Biochemistry at University College Cork. The goal of applied research in apoptosis is to develop new drugs that effectively modulate apoptosis in disease states in a safe manner. EiRx Therapeutics believes that there will be significa...

Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a privately-held specialty biopharmaceutical company, which has developed the proprietary TransMTS™ platform technology that enables local, targeted delivery of large macromolecules across skin. Their lead product, RT001, has demonstrated safety and statistically significant efficacy in Phase 2 clinical trials.


More From BioPortfolio on "Alexo Therapeutics Presents Preliminary Results from ALX148 Phase"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks